Request FREE sample PDF
Pharmacy benefit management market
LEVONORGESTREL API MARKET REPORT OVERVIEW
The global levonorgestrel API market size is anticipated to be worth USD 50 million in 2022 and is projected to touch USD 70.87 million by 2031 at a CAGR of 4.0% during the forecast period.
Levonorgestrel is a drug or a medication that is mainly used in birth control. It is a hormonal medicine that is actively used in many methods for controlling birth. It is a emergency contraceptive which is used to avoid pregnancy when other birth control measures do not succeed. It also prevents the attachment of a women’s egg to the womb. This is considered as one of the most effective methods of practicing birth control.
One of the remarkable trends that is now being witnessed in the levonorgestrel market is the discovery of once-a-month birth pills. These pills are created in such a way that they can be used only once a month and still be as effective as consuming them every day. Various non-contraceptive benefits of levonorgestrel and its suitability to treat menorrhagia act as the crucial factors that drive the market growth.
COVID-19 impact: Remote Healthcare Services and Dependency on Birth Control Increased the Market Growth
The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The spike in CAGR is attributable to the levonorgestrel API market growth and demand returning to pre-pandemic levels once the pandemic is over.
The COVID-19 pandemic hit all the markets and industries across the world. The health care industry was highly affected due to the deadly disease. Many researches were being done mainly to find out cure for COVID-19 due to which other diseases were paid less attention. It became very difficult for people to get access to even the smallest of medications and drugs.
This also created challenges in the maternity field. Remote access to health care services during pregnancy and the risks of infection promoted people to use birth control measures. Since levonorgestrel is an important method in birth control, it was extensively used which led to the levonorgestrel API market growth.
LATEST TRENDS
"Once-A-Month Birth Control Pills to Increase the Market Growth"
Many advancements and discoveries are being made in every field, especially in health care and birth control. Due to the side effects that contraceptive pills have; people hesitate to take them on a very regular basis. But the latest trend in the levonorgestrel API market is now creating opportunities for people to consume these pills once a month. The reduced frequency of consuming the pills also reduces the risk of the side effects.
One such oral contraceptive pill has been developed by the research team in the Massachusetts Institute of Technology. These pills release the levonorgestrel at a very low pace in into the stomach. The main purpose of developing this pill was to allow the patients to consume them only once a month. A research found out that the slow release of levonorgestrel API was as effective as taking one pill every day. This advancement has contributed in the growth of the market.
LEVONORGESTREL API MARKET SEGMENTATION
- By Type:
The market can be divided on the basis of type into the following segments:
Short-Acting Contraceptive API and Long-Acting Contraceptive API. Short-Acting Contraceptive API segment is projected to hold the dominant market share through 2028 the forecasting period.
- By Application:
The market can be divided on the basis of type into the following segments:
Levonorgestrel Tablet, Mixture Products, and, Hormone-releasing IUD. Levonorgestrel Tablet is predicted to dominate the market through 2028.
DRIVING FACTORS
"Various Non-Contraceptive Benefits of Levonorgestrel API to Amplify the Market Growth"
According to many researches and studies the usage of levonorgestrel is one the most effective forms of birth control for various reasons. The various non-contraceptive benefits of this medication have made it one of the best ways of avoiding pregnancy.
IUS or levonorgestrel-releasing intrauterine system is a reversible form of contraception. It is also very effective for a long period of time. Apart from being very efficient it also plays a crucial role in combining the usefulness of intrauterine contraception and hormonal contraception. This factor has contributed in the increase of levonorgestrel API market share.
"Suitability Of Levonorgestrel API to Treat Menorrhagia to Drive the Market Growth"
Along with providing many non-contraceptive benefits this medication is also prone to cure menorrhagia. Menorrhagia is a condition where women suffering from this, experience heavy menstrual blood loss which sometimes require immediate medical attention. By using levonorgestrel the amount of bleeding during menstruation is considerably reduced. The number of days of menstrual bleeding also comes down. Dysmenorrhea or painful menstruation and premenstrual conditions are also greatly relieved.
RESTRAINING FACTOR
"Side Effects and Risks Associated with Birth Control Pills to Deteriorate Market Growth"
Levonorgestrel API is mainly used in birth control pills. The frequent usage of contraceptive pills is associated with many side-effects and other health risks and concerns. Hormonal imbalances are the most common side effects and they can even persist for a very long duration of time.
Mild nausea, headache and fever can also be noticed when these pills are first used. Breast pains and migraines due to the changes in female sex hormones such as progesterone and estrogen can be seen. Weight gain, mood changes, and missed periods are also some other noticeable side effects of consuming the contraceptive pills. This can act as a major factor restraining the growth of Levonorgestrel API market.
LEVONORGESTREL API MARKET REGIONAL INSIGHTS
The region that is predicted to dominate the market during the forecast period is North America. Europe holds the second largest share in the global market after North-America. Whereas Asia Pacific is anticipated to grow exceptionally during the coming years.
There are many other reasons contributing to the growth of the market in North-America. The North-American population are developing high awareness about birth control. Also, the growing population of child-bearing women, strong and strict reimbursement of contraceptive policies and the fertility rates are some other important reasons that have increased the growth of the industry.
Key Industry Players
"Leading Players adopt Acquisition Strategies to Stay Competitive "
Several players in the market are using acquisition strategies to build their business portfolio and strengthen their market position. In addition, partnerships and collaborations are among the common strategies adopted by companies. Key market players are making R&D investments to bring advanced technologies and solutions to the market.
LIST OF TOP LEVONORGESTREL API COMPANIES
- Bayer HealthCare (Germany)
- Qinhuangdao Zizhu Pharmaceutical (China)
- Yangzhou Pharmaceutical (China)
- Lupin (India)
- Hubei Gedian Humanwell (China)
- Sterling Spa (U.S.)
- Formos (Canada)
- Huazhong Pharm (China)
- ASG Biochem (U.S.)
Report Coverage
The report provides an insight into the levonorgestrel API industry from both the demand and supply sides. Further, it also gives information on the impact of COVID-19 on the market, the driving and the restraining factors along with the regional insights. Market dynamic forces during the forecast period have also been discussed for the better understanding of the market situations.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 50 Million in 2022 |
Market Size Value By |
US$ 70.87 Million by 2031 |
Growth Rate |
CAGR of 4% from 2022 to 2031 |
Forecast Period |
2024-2031 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type, Application & Region |
Frequently Asked Questions
-
What value is levonorgestrel API the market expected to touch by 2031?
The global market levonorgestrel API is projected and estimated to touch USD 70.87 million by 2031.
-
What CAGR is the levonorgestrel API market expected to exhibit by 2031?
The levonorgestrel API market is expected to exhibit a CAGR of 4.0% by 2031.
-
Which are the driving factors of the levonorgestrel API market?
Various non-contraceptive benefits of levonorgestrel API and its suitability to treat menorrhagia act as the crucial factors that drive the levonorgestrel API market growth.
-
Which are the top companies operating in the levonorgestrel API market?
Bayer HealthCare, Qinhuangdao Zizhu Pharmaceutical, Yangzhou Pharmaceutical, Lupin, Hubei Gedian Humanwell, and, Sterling Spa, are some of the top operating companies in the levonorgestrel API market.